Basiliximab can be administered safely and effectively in a single dose on day 1 postrenal transplantation in patients receiving triple therapy with azathioprine
Transplantation proceedings.
2001 Nov-Dec ;
33 (7-8) :
3205-6.
Language English Country United States Media print
Document type Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Persistent link
https://www.medvik.cz/link/pmid11750375
PubMed
11750375
DOI
10.1016/s0041-1345(01)02364-8
PII: S0041-1345(01)02364-8
Knihovny.cz E-resources
- MeSH
- Azathioprine therapeutic use MeSH
- Basiliximab MeSH
- Safety MeSH
- Time Factors MeSH
- Immunosuppression Therapy standards MeSH
- Infections epidemiology MeSH
- Drug Therapy, Combination MeSH
- Middle Aged MeSH
- Humans MeSH
- Antibodies, Monoclonal therapeutic use MeSH
- Postoperative Complications epidemiology MeSH
- Graft Rejection epidemiology pathology prevention & control MeSH
- Recombinant Fusion Proteins * MeSH
- Histocompatibility Testing MeSH
- Kidney Transplantation immunology pathology MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
- Randomized Controlled Trial MeSH
- Geographicals
- Brazil MeSH
- Names of Substances
- Azathioprine MeSH
- Basiliximab MeSH
- Antibodies, Monoclonal MeSH
- Recombinant Fusion Proteins * MeSH
References provided by Crossref.org
